DK1119370T3 - Omstödelse af virus-fremkaldt systemisk chok og respiratorisk besvær med blokering af lymfotoksin-beta-signalvejen - Google Patents

Omstödelse af virus-fremkaldt systemisk chok og respiratorisk besvær med blokering af lymfotoksin-beta-signalvejen

Info

Publication number
DK1119370T3
DK1119370T3 DK99950270T DK99950270T DK1119370T3 DK 1119370 T3 DK1119370 T3 DK 1119370T3 DK 99950270 T DK99950270 T DK 99950270T DK 99950270 T DK99950270 T DK 99950270T DK 1119370 T3 DK1119370 T3 DK 1119370T3
Authority
DK
Denmark
Prior art keywords
respiratory distress
blocking
lymphotoxin
reversal
virus
Prior art date
Application number
DK99950270T
Other languages
Danish (da)
English (en)
Inventor
Jeff Browning
Maryann Puglielli
Rafi Ahmed
Original Assignee
Biogen Idec Inc
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Univ Emory filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1119370T3 publication Critical patent/DK1119370T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • C07K16/242Lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK99950270T 1998-10-09 1999-10-08 Omstödelse af virus-fremkaldt systemisk chok og respiratorisk besvær med blokering af lymfotoksin-beta-signalvejen DK1119370T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10366298P 1998-10-09 1998-10-09

Publications (1)

Publication Number Publication Date
DK1119370T3 true DK1119370T3 (da) 2006-10-02

Family

ID=22296372

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99950270T DK1119370T3 (da) 1998-10-09 1999-10-08 Omstödelse af virus-fremkaldt systemisk chok og respiratorisk besvær med blokering af lymfotoksin-beta-signalvejen

Country Status (27)

Country Link
US (3) US20020001585A1 (el)
EP (1) EP1119370B1 (el)
JP (2) JP4713738B2 (el)
KR (1) KR100888832B1 (el)
CN (1) CN1200733C (el)
AT (1) ATE329618T1 (el)
AU (1) AU777492C (el)
BR (1) BR9915025A (el)
CA (1) CA2344049C (el)
CY (1) CY1105059T1 (el)
CZ (1) CZ20011272A3 (el)
DE (1) DE69931944T2 (el)
DK (1) DK1119370T3 (el)
EA (1) EA006703B1 (el)
EE (1) EE04661B1 (el)
ES (1) ES2267294T3 (el)
HU (1) HUP0103773A3 (el)
IL (2) IL142284A0 (el)
IS (1) IS2514B (el)
NO (1) NO326905B1 (el)
NZ (1) NZ510560A (el)
PL (1) PL195264B1 (el)
PT (1) PT1119370E (el)
SG (1) SG121778A1 (el)
SK (1) SK4662001A3 (el)
TR (1) TR200100974T2 (el)
WO (1) WO2000021558A1 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
CN1200733C (zh) * 1998-10-09 2005-05-11 拜奥根有限公司 阻断淋巴毒素β与其受体结合的物质在制备药物中的应用
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
EP1674575B1 (en) * 2000-04-12 2010-10-06 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US20050163782A1 (en) * 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
KR20060132006A (ko) * 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
MX2009004134A (es) 2006-10-20 2009-08-12 Biogen Idec Inc Tratamiento de trastornos de desmielinizacion con el receptor de linfotoxina beta soluble.
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP3750554A3 (en) * 2007-09-18 2021-07-28 La Jolla Institute for Allergy and Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
CN106591446A (zh) * 2016-12-07 2017-04-26 中国人民解放军军事医学科学院微生物流行病研究所 细胞通路调控分子在作为药物靶点及诊断ebov感染中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
ES2157889T3 (es) * 1990-06-27 2001-09-01 Biogen Inc Linfotoxina complejada de superficie.
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US5670149A (en) * 1990-06-27 1997-09-23 Biogen, Inc. Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH08507201A (ja) 1992-12-04 1996-08-06 バイオジェン,インコーポレイテッド リンホトキシン‐β、リンホトキシン‐β複合体、それらの薬学的な調製物および治療への使用
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
EP0809510B1 (en) 1995-01-26 2004-06-09 Biogen, Inc. Lymphotoxin-alpha/beta complexes and anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
HU226467B1 (en) * 1996-10-25 2008-12-29 Biogen Idec Inc Soluble lymphotoxin-beta receptors and use of anti-lymphotoxin receptor antibodies for production of pharmaceutical compostions for the treatment of autoimmunological diseases
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
CN1200733C (zh) * 1998-10-09 2005-05-11 拜奥根有限公司 阻断淋巴毒素β与其受体结合的物质在制备药物中的应用
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
AU2003248782A1 (en) * 2002-07-01 2004-01-19 Biogen Idec Ma Inc. Humanized anti-lymphotoxin beta receptor antibodies

Also Published As

Publication number Publication date
CZ20011272A3 (cs) 2001-09-12
BR9915025A (pt) 2001-08-14
SK4662001A3 (en) 2001-11-06
ATE329618T1 (de) 2006-07-15
PL195264B1 (pl) 2007-08-31
EA200100430A1 (ru) 2001-10-22
DE69931944T2 (de) 2007-02-08
CY1105059T1 (el) 2010-03-03
NO20011757L (no) 2001-06-08
CN1323223A (zh) 2001-11-21
NO326905B1 (no) 2009-03-16
CA2344049C (en) 2009-12-15
EE200100211A (et) 2002-08-15
EP1119370A1 (en) 2001-08-01
ES2267294T3 (es) 2007-03-01
EE04661B1 (et) 2006-08-15
JP2010155852A (ja) 2010-07-15
WO2000021558A1 (en) 2000-04-20
IS5882A (is) 2001-03-09
AU777492B2 (en) 2004-10-21
SG121778A1 (en) 2006-05-26
JP2002527403A (ja) 2002-08-27
AU777492C (en) 2005-05-26
EP1119370B1 (en) 2006-06-14
EA006703B1 (ru) 2006-02-24
CA2344049A1 (en) 2000-04-20
HUP0103773A2 (hu) 2002-01-28
JP4713738B2 (ja) 2011-06-29
IS2514B (is) 2009-06-15
IL142284A0 (en) 2002-03-10
KR100888832B1 (ko) 2009-03-17
DE69931944D1 (de) 2006-07-27
NO20011757D0 (no) 2001-04-06
PL347177A1 (en) 2002-03-25
HUP0103773A3 (en) 2003-10-28
IL142284A (en) 2009-11-18
AU6296499A (en) 2000-05-01
PT1119370E (pt) 2006-09-29
KR20010080073A (ko) 2001-08-22
US7452530B2 (en) 2008-11-18
WO2000021558A9 (en) 2001-05-25
US20090087403A1 (en) 2009-04-02
NZ510560A (en) 2003-09-26
US20020001585A1 (en) 2002-01-03
CN1200733C (zh) 2005-05-11
US20040198635A1 (en) 2004-10-07
TR200100974T2 (tr) 2001-11-21

Similar Documents

Publication Publication Date Title
DK1119370T3 (da) Omstödelse af virus-fremkaldt systemisk chok og respiratorisk besvær med blokering af lymfotoksin-beta-signalvejen
PL350456A1 (en) N−cyanomethylamides as protease inhibitors
MX9805539A (es) Uso de un agonista del receptor activado proliferador de peroxisomas alfa y del receptor activado proliferador de peroxisomas gamma, para el tratamiento del sindrome x.
DK1414451T3 (da) Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist
DK1102583T3 (da) Behandling af tilvænning af nicotin og tilvænningsrelateret adfærd
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
NO981436L (no) Farmas÷ytiske angiostatiske dipeptidsammensetninger og anvendelse derav
DK0867184T3 (da) Anvendelse af tiagabin til behandling af søvnforstyrrelser
TR199901772T2 (el)
PL361179A1 (en) Treatment of cancers
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
DK1052991T3 (da) Topisk anvendelse af loperamid til behandling af mikrobielle infektioner
NO982854D0 (no) Nitrogenoksyd (NO) syntetase-inhibitor for Õ behandle eller forebygge type II diabetes
DK1311279T3 (da) Behandling af hepatitis C med thymosin, interferon og ribavirin
RO94381B1 (ro) Produs medicamentos pentru sustinerea efortului de durata medie si lunga
FI972637A0 (fi) K-ryhmän vitamiinin käyttö lisäkilpirauhasen liikatoiminnan hoitoon
ZA833161B (en) N2-(substituted)carboxymethyl-n6-(substituded)-lysyl and a-(e-aminoalkyl)glycyl amino acid antihypertensive agents
DK1032407T3 (da) Anvendelse af putamen ovi
TR199801043T2 (xx) Mide-ba��rsak bozukluklar�n�n �nlenmesi ve tedavisi i�in bizmut i�eren bile�imler.
IT8430886V0 (it) Apparecchio per la ionizzazione negativa dell'ossigeno contenuto nell'aria ambiente, caratterizzato dal grado molto elevato di detta ionizzazione e dalla possibilita'd'impiego tanto in campo igienico e profilattico quanto in campo terapeutico.
CO4940419A1 (es) Compuestos farmaceuticos y su utilizacion en el tratmiento de trastornos del sistema central
ITRM910634A1 (it) Slip (mutande) antiaids in lattice di gomma sagomate, unisex, che consentono di avere rapporti sessuali di ogni tipo con elevata
SE0000234D0 (sv) Antifungal drug composition and drug delivery system